A unique presentation of 5-fluorouracil (5-FU) induced cerebral encephalopathy

被引:4
作者
Naik, Shailendra S. [1 ]
Vanidassane, Ilavarasi [2 ]
Dhamija, Ekta [1 ]
Sharma, Atul [2 ]
机构
[1] AIIMS, IRCH, Dept Radiodiag, New Delhi, India
[2] AIIMS, Dept Med Oncol, IRCH, New Delhi 110029, India
关键词
Chemotherapy; drug-induced encephalopathy; encephalopathy; 5-fluorouracil;
D O I
10.4103/ijri.IJRI_17_19
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
5-Fluorouracil (5-FU), a commonly used antimetabolite and antineoplastic agent, has been approved for the treatment of various cancers. It is associated with systemic side-effects such as gastrointestinal problems, neutropenia. 5-FU-related encephalopathy is very rarely reported. Imaging with computed tomography (CT) and magnetic resonance imaging (MRI) plays a key role in diagnosing and monitoring the changes. Since the prognosis of cerebral involvement is usually good if recognized and treated in time, the reporting radiologist and treating physician should be familiar with them. We present a rare case of 5-FU-induced encephalopathy that was diagnosed based on her clinical and MRI findings and managed successfully.
引用
收藏
页码:214 / 217
页数:4
相关论文
共 50 条
  • [31] Etoposide, leucovorin (LV) and 5-fluorouracil (5-FU) in 5-FU+LV pre-treated patients with advanced colorectal cancer
    Tsavaris, N
    Kosmas, C
    Gennatas, K
    Vadiaka, M
    Skopelitis, E
    Xila, V
    Rokana, S
    Margaris, E
    Zografos, G
    Papastratis, G
    Kouraklis, G
    JOURNAL OF CHEMOTHERAPY, 2002, 14 (04) : 406 - 411
  • [32] 120-HOUR 5-FLUOROURACIL (5-FU) CONTINUOUS INFUSION (CI) PLUS BCNU IN ADVANCED COLORECTAL-CANCER
    VILLARGRIMALT, A
    CANDEL, MT
    DELGADO, F
    GARCIAREINOSO, J
    SANCHIS, C
    VICIANO, V
    ASENCIO, F
    MARTINEZABAD, M
    AGUILO, J
    SANCHEZ, JJ
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1991, 14 (05): : 387 - 392
  • [33] CARBOPLATIN (CBDCA), 5-FLUOROURACIL (5-FU) AND MITOXANTRONE (DHAD) - AN EFFECTIVE AND WELL TOLERATED REGIMEN FOR METASTATIC BREAST-CANCER
    HIDALGO, OF
    GONZALEZ, FG
    VIEITEZ, JM
    REBOLLO, J
    TANGCO, E
    HERRANZ, P
    ANNALS OF ONCOLOGY, 1992, 3 (07) : 545 - 547
  • [34] Suramin in combination with 5-fluorouracil (5-FU) and leucovorin (LV) in metastatic colorectal cancer patients resistant to 5-FU+LV-based chemotherapy
    Falcone, A
    Pfanner, E
    Brunetti, I
    Allegrini, G
    Lencioni, M
    Galli, C
    Masi, G
    Danesi, D
    Antonuzzo, A
    Del Tacca, M
    Conte, PF
    TUMORI, 1998, 84 (06) : 666 - 668
  • [35] Diagnosis and management of 5-fluorouracil (5-FU)-induced acute leukoencephalopathy: lessons learnt from a single-Centre case series
    Neethu Jose
    Anjana Joel
    Rajesh Joseph Selvakumar
    Jebakarunya Ramireddy
    Ajoy Oommen John
    Josh Thomas Georgy
    Ashish Singh
    Thomas Samuel Ram
    Journal of the Egyptian National Cancer Institute, 34
  • [36] Diagnosis and management of 5-fluorouracil (5-FU)-induced acute leukoencephalopathy: lessons learnt from a single-Centre case series
    Jose, Neethu
    Joel, Anjana
    Selvakumar, Rajesh Joseph
    Ramireddy, Jebakarunya
    John, Ajoy Oommen
    Georgy, Josh Thomas
    Singh, Ashish
    Ram, Thomas Samuel
    JOURNAL OF THE EGYPTIAN NATIONAL CANCER INSTITUTE, 2022, 34 (01)
  • [37] BIOCHEMICAL MODULATION OF 5-FLUOROURACIL (5-FU) BY LEUCOVORIN (LCV) - THYMIDYLATE SYNTHASE ACTIVITY AND NUCLEOSIDE INCORPORATION INTO DNA
    KAU, B
    RIEGER, M
    SAUER, H
    ONKOLOGIE, 1990, 13 (06): : 453 - 457
  • [38] Assessment of surface concentrations in resorbable ocular implants: Controlled drug delivery devices for 5-fluorouracil (5-FU).
    Milne, P
    Gautier, S
    Parel, JM
    Jallet, V
    OPHTHALMIC TECHNOLOGIES VII, PROCEEDINGS OF, 1997, 2971 : 137 - 146
  • [39] Absorption and distribution characteristics of 5-fluorouracil (5-FU) after an application to the liver surface in rats in order to reduce systemic side effects
    Kodama, Yukinobu
    Fumoto, Shintaro
    Nishi, Junya
    Nakashima, Mikiro
    Sasaki, Hitoshi
    Nakamura, Junzo
    Nishida, Koyo
    BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2008, 31 (05) : 1049 - 1052
  • [40] Plasma and salivary pharmacokinetics of 5-fluorouracil (5-FU) in patients with metastatic colorectal cancer receiving 5-FU bolus plus continuous infusion with high-dose folinic acid
    Joulia, JM
    Pinguet, F
    Ychou, M
    Duffour, J
    Astre, C
    Bressolle, F
    EUROPEAN JOURNAL OF CANCER, 1999, 35 (02) : 296 - 301